<DOC>
	<DOCNO>NCT01462266</DOCNO>
	<brief_summary>The purpose study examine insulin-sparing effect sitagliptin 100 mg once-daily compare placebo 24 week participant type 2 diabetes mellitus inadequate glycemic control insulin alone combination metformin . The primary hypothesis study 24 week , sitagliptin reduces dose insulin relative placebo .</brief_summary>
	<brief_title>Study Sitagliptin Treatment Type 2 Diabetes Mellitus With Inadequate Glycemic Control Insulin ( MK-0431-260 )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>type 2 diabetes mellitus one follow criterion : diagnose diabetes age 40 year insulin therapy initiate least 3 year follow diagnosis diagnose diabetes age 40 year insulin start early 3 year diagnosis , fast Cpeptide great 0.7 ng/mL must least 18 year age less equal 80 year age ( participant India : must least 18 year age less equal 65 year age ) stable regimen insulin least 10 week without metformin ( least 1500 mg/day ) and/or sulfonylurea least 10 week highly unlikely become pregnant ( reproductive potential agrees remain abstinent use ( partner use ) acceptable method birth control study 14 day last dose study medication treat dipeptidyl peptidase IV ( DPP4 ) inhibitor , thiazolidinedione ( TZD ) , glucagonlike peptide1 ( GLP1 ) mimetic analogue , within past 12 week currently treatment daily use ( one injection per day ) preprandial shortacting rapidacting insulin alone part basal/bolus insulin regimen symptomatic hyperglycemia require immediate initiation , adjustment , addition antihyperglycemic therapy history 2 episode hypoglycemia result seizure , coma , loss consciousness , recurrent ( â‰¥3 time per week ) episodes hypoglycemia past 8 week history ketoacidosis appropriate agree target fast glucose 72100 mg/dL [ 4.05.6 mmol/L ] likely require treatment corticosteroid undergone surgical procedure within 4 week plan major surgery study currently treat hyperthyroidism thyroid hormone therapy stable dose least 6 week history active liver disease ( nonalcoholic hepatic steatosis ) new worsen sign symptom coronary heart disease congestive heart failure within past 3 month , follow disorder within past 3 month : acute coronary syndrome coronary artery intervention stroke transient ischemic neurological disorder systolic blood pressure great 160 mm Hg diastolic blood pressure great 90 mm Hg human immunodeficiency virus ( HIV ) severe peripheral vascular disease clinically important hematological disorder history malignancy le 5 year study start , except adequately treat basal cell squamous cell skin cancer situ cervical cancer positive urine pregnancy test pregnant breastfeeding , expect conceive donate egg study user recreational illicit drug recent history drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>